Clinical Trials Logo

Renal Cell Carcinoma clinical trials

View clinical trials related to Renal Cell Carcinoma.

Filter by:

NCT ID: NCT04758507 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Renal Cell Carcinoma

TACITO
Start date: February 18, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Renal cell carcinoma (RCC) is the sixth most common cancer in men and the eighth in women in the USA. In Italy RCC incidence was 11500 new cases in 2017, while mortality was 3371 cases in 2015. Increasing evidence suggests that response to immune checkpoint inhibitors (ICIs), a novel treatment for advanced RCC (aRCC) and other epithelial tumors, can be influenced by the patient gut microbiota. Fecal microbiota transplantation (FMT) is a novel therapeutic option based on the restoration of healthy gut microbiota, and is the most effective therapy for recurrent C. difficile infection, and preliminary nonrandomized findings show that FMT is able to improve efficacy of ICIs in patients with advanced melanoma. The aim of this study is to evaluate, through a randomized controlled trial, the efficacy of targeted FMT (from donors who are responding to ICI. in improving response rates to ICIs in subjects with aRCC.

NCT ID: NCT04704219 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

KEYNOTE-B61
Start date: February 23, 2021
Phase: Phase 2
Study type: Interventional

This study is being performed as a single-arm open-label study in order to rapidly provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with previously untreated advanced/metastatic non-clear cell renal cell carcinoma.

NCT ID: NCT04508725 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)

Start date: December 5, 2020
Phase: N/A
Study type: Interventional

To assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by power Doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment

NCT ID: NCT04503148 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Anesthesia and Cancer Study: Renal Cell Carcinoma

Start date: September 22, 2020
Phase: N/A
Study type: Interventional

This study investigates the influence of type of anesthesia on recurrence and survival of renal cell carcinoma in patients undergoing nephrectomy. The participants will be allocated to either the group receiving the total intravenous anesthesia (TIVA) using propofol or the group receiving the inhaled anesthetics, such as sevoflurane or desflurane.

NCT ID: NCT04495257 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

Start date: September 14, 2020
Phase: Phase 1
Study type: Interventional

This study is a Phase 1, open-label, single institution, dose escalation and dose expansion study to evaluate the efficacy, safety, and tolerability of APX005M in combination with nivolumab and ipilimumab in patients with advanced melanoma and RCC.

NCT ID: NCT04438083 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

Start date: June 16, 2020
Phase: Phase 1
Study type: Interventional

This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX130 in subjects with relapsed or refractory renal cell carcinoma.

NCT ID: NCT04416646 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma

ZEBRA
Start date: February 27, 2019
Phase:
Study type: Observational

The purpose of this study is to evaluate the safety and efficacy of Cabozantinib in the treatment of patients with renal cell carcinoma.

NCT ID: NCT04337970 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

Start date: April 6, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Researchers are doing this study to find out if the combination of the drugs axitinib and talazoparib is a safe and effective treatment for people with your previously treated advanced kidney cancer. Researchers will look for the highest dose of talazoparib that causes few or mild side effects when given in combination with a standard dose of axitinib.

NCT ID: NCT04267120 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

Start date: July 29, 2020
Phase: Phase 2
Study type: Interventional

This is a single-arm, multicenter, phase 2 study of lenvatinib in combination with pembrolizumab (lenvatinib 20 mg/day + pembrolizumab 200mg q3weeks) in subjects with unresectable advanced or metastatic non-clear cell renal carcinoma who have not received any chemotherapy for advanced disease.

NCT ID: NCT04234113 Active, not recruiting - Ovarian Cancer Clinical Trials

Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors

Start date: June 13, 2019
Phase: Phase 1
Study type: Interventional

A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors